Minimally Invasive Glaucoma Surgery vs Durysta Implant: Understanding the Difference

Minimally Invasive Glaucoma Surgery vs Durysta Implant: Understanding the Difference

MIGS, short for Minimally Invasive Glaucoma Surgery, and Durysta implants are two of the most commonly used procedures to treat glaucoma. While both procedures aim to address the same condition, that is where the similarities end. MIGS, as the name suggests, is a modern minimally invasive procedure that increases safety for patients, while significantly reducing the chance of complications. Durysta implant, on the other hand, is a drug to reduce intraocular pressure, which is administered in an outpatient procedure. Continuing on the subject, let’s take a closer look at each of the treatment options. Read on.

Minimally Invasive Glaucoma Surgery

The eye has multiple chambers, each having a different fluid. Under normal conditions, the liquid in the anterior chamber of the eye is constantly circulating in and out of the chamber, a process that is obstructed in glaucoma cases, resulting in an increase in intraocular pressure. MIGS is performed to correct any obstruction in the eye. Based on the therapeutic approach, Minimally Invasive Glaucoma Surgery can be performed for different objectives, such as:

• Improving the natural flow of fluid
• Shunting fluid out of the eye
• Decreasing the production of aqueous fluid
• Implanting medication inside the anterior chamber

It is also important to mention that there are multiple types of MIGS, but all of them can be performed on an outpatient basis.

Durysta Treatment for Glaucoma

Durysta implant is a new treatment option for glaucoma, approved by the FDA in March 2020. Also called “bimatoprost implant”, Durysta treatment for glaucoma involves administration of a drug to address ocular hypertension or open-angle glaucoma. During the procedure, a surgeon administers the drug by inserting the tip of a sterile applicator into the eye’s anterior chamber, after which the patient is required to sit for about an hour. The implant steadily releases the drug over a 90-day period, to stimulate the outflow of eye fluid and reduce the intraocular pressure.

Wrap Up

Glaucoma is a degenerative disorder that calls for immediate medical intervention once a patient starts noticing any of its symptoms, as prolonged delay can cause irreversible damage to the eye. If you or a loved one is noticing any of the symptoms of glaucoma, waste no time in booking a consultation with a reputable glaucoma specialist such as Texas Eye and Cataract. Since inception, our team has successfully treated countless cases of glaucoma and the next success story could be yours. To book a consultation with one of our glaucoma specialists, click here. If you have any questions, you can write to us at info@teceyecare.com or simply call 469-505-2020 (Monday through Friday, 9:00AM to 5:00PM).

‍